Oncologists’ preferences for first-line treatment of ALK-positive metastatic NSCLC in the United States: a discrete choice experiment
We identified two oncologist groups with distinct preferences for treatment attributes. Given various 1 L ALK+ mNSCLC treatments, clinical decision-making balances multiple objectives.
Authors
- Marlon Graf (ORCID: https://orcid.org/0000-0002-6240-8867)
- Kathryn F. Mileham (ORCID: https://orcid.org/0000-0003-1334-7743)
- Christopher G. Danes
- Pedro Labisa
- Luis Hernández (ORCID: https://orcid.org/0000-0002-9532-546X)
- Laura Panattoni (ORCID: https://orcid.org/0000-0002-5081-5043)
- Grace Gahlon
- Nicole Bariahtaris
Institutions
- Levine Cancer Institute (US)
- Precision for Medicine (United States) (US)
- Laboratório Edol (Portugal) (PT)
- Takeda (United States) (US)
- Precision Research (United States) (US)
- Wake Forest University (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1080/14796694.2025.2584290
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00